Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa
Dermatology · 2023
DOI: 10.1159/000531558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology, 2023. Verfasst von Maria Argyropoulou und 11 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Results of randomized clinical trials show great variation in response to treatment with adalimumab (ADA) in hidradenitis suppurativa (HS). This varied response may be associated with genetic polymorphisms.
Objectives
The aim of the study was to study the association between carriage of single nucleotide polymorphisms (SNPs) in the promoter of the tumor necrosis factor (TNF) gene and their response to ADA.
Methods
Patients with moderate to severe HS who received ADA treatment for at least 12 weeks were enrolled. SNPs were analyzed with PCR-restriction fragment length polymorphism. Hidradenitis Suppurativa Clinical Response (HiSCR) score, International Hidradenitis Suppurativa Severity Scoring System 4 (IHS4) score, inflammatory lesion (AN) count, and draining tunnel (dT) count were collected at weeks 0, 12, 24, 36, and 48.
Results
HiSCR response after 12 weeks of ADA treatment was 71.8% among carriers of the common GGG haplotype and 50.0% among carriers of minor frequency SNP haplotypes (p: 0.031; odds ratio: 0.39). This significant difference persisted until week 36. Carriers of minor frequency SNP haplotypes also had a lower relative decrease of the AN count at weeks 12 and 24; the dT count and IHS4 were not statistically different between the two groups.
Conclusions
Carriage of at least one minor frequency SNP haplotype of the promoter of the TNF gene is associated with a decreased response to ADA. This association may have an impact on treatment decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- 2nd Department of Dermatology and Venereology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Department of Dermatology, The Ohio State University, Columbus, Ohio, USA.
Zitieren
APA
Argyropoulou, M., Trigoni, A., Kaffenberger, J., Stergianou, D., Damoraki, G., Mingiani, E., Micha, S., Krispinsky, A., Meltzanidou, P., Kanni, T., Lazaridou, E., & Giamarellos-Bourboulis, E. J. (2023). Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa. Dermatology. https://doi.org/10.1159/000531558
Vancouver
Argyropoulou M, Trigoni A, Kaffenberger J, Stergianou D, Damoraki G, Mingiani E, et al. Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa. Dermatology. 2023. doi:10.1159/000531558
BibTeX
@article{Argyropoulou2023,
author = {Argyropoulou, Maria and Trigoni, Anastasia and Kaffenberger, Jessica and Stergianou, Dimitra and Damoraki, Georgia and Mingiani, Elissavet and Micha, Styliani and Krispinsky, Andrew and Meltzanidou, Parthena and Kanni, Theodora and Lazaridou, Elizabeth and Giamarellos-Bourboulis, Evangelos J},
title = {Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa},
journal = {Dermatology},
year = {2023},
doi = {10.1159/000531558}
}
EUVIMED